Hospitals and Private Practice: US Clinical Trial Locations
A data analysis focusing on where US investigators conduct clinical trials.
Clinical trial sites in many countries are often heavily concentrated in hospitals and similar institutions. Even within the United States many health care professionals probably think that is the case for the United States as well. Data from Open Payments, the database mandated by the Sunshine Act, definitely show that a large proportion of clinical trial work is done in physicians’ practices rather than hospitals.
As of 2015 there were 5,564 registered US hospitals, and only 22% of these participate in commercially funded clinical trials. Open Payments refers to these hospitals as teaching hospitals. A teaching hospital is broadly defined to include any hospital anywhere in the United States or its territories receiving Medicare, as well as indirect or direct graduate medical education payments.
There are any number of reasons a study may be done at an institution rather than a private practice. The study indication of course leaps out as an explanation. In-patient indications, for instance, must usually be done in hospitals. In addition there might be particular expertise or a specific opinion leader on staff at a particular hospital. In addition study conduct costs and overheads at hospitals often exceed comparable private practice costs. Open Payments indicates 80% of all investigator payments go to physicians working in private practice. Few doctors conduct clinical trials in teaching hospitals alone. The large majority do all their clinical trial work in private practice settings. Slightly over one in ten work at both teaching hospitals and private practice.
Where US Investigators Conduct Clinical Trials, 2016
Institutions Only
Private Only
Both
12%
75%
13%
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
